Ret Antibody (C-3): sc-365943

Ret Antibody (C-3) is a mouse monoclonal IgG1 kappa light chain antibody that detects Ret protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Ret Antibody (C-3) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. The Ret proto-oncogene plays a crucial role in cell signaling, particularly in the glial cell line-derived neurotrophic factor (GDNF) signaling pathway, which is essential for the development and maintenance of the nervous system. Ret protein is primarily located on the cell membrane, where Ret (C-3) antibody functions as a receptor tyrosine kinase, facilitating communication between cells and their environment. This localization is vital for mediating cellular responses to growth factors, influencing processes such as cell differentiation, survival, and proliferation. Notably, aberrations in the Ret gene, including tumor-specific rearrangements, have been implicated in various cancers, particularly papillary thyroid carcinoma, where anti-Ret antibody (C-3) leads to the production of fusion proteins that exhibit constitutive activation of the Ret signaling pathway. Such alterations underscore Ret protein′s importance in both normal physiology and disease, making Ret (C-3) monoclonal antibody an invaluable tool for researchers studying its function and implications in cancer biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Ret Antibody (C-3) References:

1. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas.  |  Lanzi, C., et al. 1992. Oncogene. 7: 2189-94. PMID: 1437145
2. Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells.  |  Takahashi, M., et al. 1991. Oncogene. 6: 297-301. PMID: 2000222
3. Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line.  |  Tahira, T., et al. 1990. Oncogene. 5: 97-102. PMID: 2181380
4. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.  |  Grieco, M., et al. 1990. Cell. 60: 557-63. PMID: 2406025
5. Crosstalk of parkin and Ret in dopaminergic neurons.  |  Kramer, ER. 2015. Oncotarget. 6: 15704-5. PMID: 26202959
6. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.  |  Takahashi, M., et al. 1988. Oncogene. 3: 571-8. PMID: 3078962
7. Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.  |  Ding, S., et al. 2020. Biomed Pharmacother. 132: 110901. PMID: 33125973
8. Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.  |  Adashek, JJ., et al. 2021. Mol Cancer Ther. 20: 1769-1776. PMID: 34493590
9. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.  |  Rosen, EY., et al. 2022. Nat Commun. 13: 1450. PMID: 35304457
10. RET is a sex-biased regulator of intestinal tumorigenesis.  |  Koester, ST., et al. 2023. Front Gastroenterol (Lausanne). 2: PMID: 39148929
11. Functional receptor for GDNF encoded by the c-ret proto-oncogene.  |  Trupp, M., et al. 1996. Nature. 381: 785-9. PMID: 8657281
12. RET mutations in human disease.  |  Pasini, B., et al. 1996. Trends Genet. 12: 138-44. PMID: 8901418

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Ret Antibody (C-3) has 5 citations in a variety of scientific publications.

Primary antibodies like Anti-Ret Antibody (C-3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Ret Antibody (C-3) Specifications

Alternate Product Name: Ret

Product Clone Name: C-3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 31-330

Epitope Target: a region conserved between Ret isoforms A and C

Epitope Species: human

Product Reactivity/Detection: Ret isoforms A and C

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 5 citations in various scientific publications

Available Conjugates/Forms for Ret Antibody (C-3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin